Thioguanine Tablet
NDC Package 46014-6302-5

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Thioguanine tablets is thioguanine is used to treat a certain type of cancer (acute myeloid leukemia-AML). This formulation utilizes a tablet delivery system. Marketed by Excella Gmbh & Co. Kg, this product is identified by NDC 46014-6302.

Identification & Billing

NDC Package Code
46014-6302-5
Package Description
1 BOTTLE in 1 CARTON / 25 TABLET in 1 BOTTLE
Product Code
46014-6302
11-Digit Billing Format
46014630205

Clinical Specifications

Proprietary Name
Thioguanine
Non-Proprietary Name
Thioguanine
Substance Name
Thioguanine
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Active Ingredient(s)
THIOGUANINE 40 mg/1
Usage Information
Thioguanine is used to treat a certain type of cancer (acute myeloid leukemia-AML). It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Excella Gmbh & Co. Kg
Product Type
Human Prescription Drug
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
05-15-2023
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 46014-6302-5 identifies a specific commercial package of 1 bottle in 1 carton / 25 tablet in 1 bottle of Thioguanine (UNFINISHED drug), a human prescription drug labeled by Excella Gmbh & Co. Kg. This tablet is formulated for use and contains thioguanine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Excella Gmbh & Co. Kg on May 15, 2023. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Thioguanine is used to treat a certain type of cancer (acute myeloid leukemia-AML). It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

How is this Excella Gmbh & Co. Kg product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 46014630205. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
46014-6302-5
11-Digit CMS (5-4-2)
46014-6302-05

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.